TSPAN 33 IS A CANDIDATE FOR ANTIBODY TARGETED THERAPY FOR THE TREATMENT OF B CELL HODGKIN LYMPHOMAS
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
N/A
Issued Date -
Aug 18, 2016
app pub date -
Dec 20, 2013
filing date -
Dec 21, 2012
priority date (Note) -
Published
status (Latency Note)
Importance
Abstract
A method of treating a disease associated with activated B lymphocytes expressing Tetraspanin 33 (TSPAN33/BAAM). The disease can be, for example, lymphoma or an immune disease. The method includes administering an anti-TSPAN33/BAAM antibody to a patient in need of such treatment in an amount effective to treat the disease. Methods of purifying activated B cells and identifying activated and/or diseased B cells are also provided.
First Claim
Family
International Classification(s)
- [Classification Symbol]
- [Patents Count]
Cited Art Landscape
Patent Citation Ranking
Advertisement
Advertisement
Advertisement
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully